Article info

Original research
Statins act as transient type I interferon inhibitors to enable the antitumor activity of modified vaccinia Ankara viral vectors

Authors

  • Shirley Tenesaca Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, SpainNavarra Institute for Health Research (IDISNA), Pamplona, Spain PubMed articlesGoogle scholar articles
  • Marcos Vasquez Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, SpainNavarra Institute for Health Research (IDISNA), Pamplona, Spain PubMed articlesGoogle scholar articles
  • Maite Alvarez Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, SpainNavarra Institute for Health Research (IDISNA), Pamplona, Spain PubMed articlesGoogle scholar articles
  • Itziar Otano Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, SpainNavarra Institute for Health Research (IDISNA), Pamplona, Spain PubMed articlesGoogle scholar articles
  • Myriam Fernandez-Sendin Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, SpainNavarra Institute for Health Research (IDISNA), Pamplona, Spain PubMed articlesGoogle scholar articles
  • Claudia Augusta Di Trani Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, SpainNavarra Institute for Health Research (IDISNA), Pamplona, Spain PubMed articlesGoogle scholar articles
  • Nuria Ardaiz Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, SpainNavarra Institute for Health Research (IDISNA), Pamplona, Spain PubMed articlesGoogle scholar articles
  • Celia Gomar Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, SpainNavarra Institute for Health Research (IDISNA), Pamplona, Spain PubMed articlesGoogle scholar articles
  • Angela Bella Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, SpainNavarra Institute for Health Research (IDISNA), Pamplona, Spain PubMed articlesGoogle scholar articles
  • Fernando Aranda Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, SpainNavarra Institute for Health Research (IDISNA), Pamplona, Spain PubMed articlesGoogle scholar articles
  • José Medina-Echeverz Bavarian Nordic GmbH, Martinsried, Germany PubMed articlesGoogle scholar articles
  • Ignacio Melero Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, SpainNavarra Institute for Health Research (IDISNA), Pamplona, SpainCentro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, SpainDepartment of Oncology, Clínica Universidad de Navarra, Pamplona, Spain PubMed articlesGoogle scholar articles
  • Pedro Berraondo Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, SpainNavarra Institute for Health Research (IDISNA), Pamplona, SpainCentro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Pedro Berraondo; pberraondol{at}unav.es
View Full Text

Citation

Tenesaca S, Vasquez M, Alvarez M, et al
Statins act as transient type I interferon inhibitors to enable the antitumor activity of modified vaccinia Ankara viral vectors

Publication history

  • Accepted June 27, 2021
  • First published July 28, 2021.
Online issue publication 
January 26, 2023
  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.